Stock Taper
SCREENER COMPARE ANY 2 STOCKS
RLAY
RELAY THERAPEUTICS, INC.
NASDAQ
$18.77
▼ DOWN 3.35% (-0.65)

KEY STATISTICS

Market Cap$4.11 B
52w High$21.27
52w Low$3.57
Dividend Yield—
Frequency—
P/E-11.96
Volume2.76M
Shares Out.219.14M

COMPANY

LEADERSHIP

Sanjiv K. Patel
CHIEF EXECUTIVE
Sanjiv K. Patel

COMPENSATION 2026

Salary$707,846
Stock Awards$0
Incentive Plan Pay$424,708
All Other Comp.$0
Total$4,646,454

ABOUT

SECTOR
Healthcare
WENT PUBLIC
July 16, 2020
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
202

PRICE TARGET

Target High$31.00
Target Low$18.00
Target Median$27.50
Target Consensus$26.25

UPCOMING EARNINGS

DateNov 5, 2026
DayThursday
Rev. Est.$1.62M
NOV
5
THU

PRICE

$18.77 ▼ DOWN 3.35% (−$0.65)
$18.60$18.80$19.00$19.209:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM18.77

About Relay Therapeutics, Inc.

https://www.relaytx.com ↗

Relay Therapeutics, Inc. is a Cambridge-based clinical-stage company developing precision medicines targeting oncology and genetic diseases, with lead candidates like FGFR2, mutant-PI3Kα, and PTP1B inhibitors.

INDUSTRY

Biotechnology

A PRODUCT RELAY THERAPEUTICS, INC. IS KNOWN FOR

Zovegalisib (RLY-2608)
Zovegalisib (RLY-2608)

Zovegalisib is an investigational oral PI3Kα inhibitor in late-stage trials for HR+, HER2-, PI3Kα-mutated advanced breast cancer, representing Relay Therapeutics' lead candidate with potential as a targeted therapy.

COMPETITORS

COMPETITOR
CELC COMPARE
LLY COMPARE
NVS COMPARE
PFE COMPARE
TGTX COMPARE

Revenue by Products

IconPRODUCTQ1-2022Q2-2022Q3-2022Q2-2025
Operating Segments— — — $677K
License$200K $300K ▲$300K —

ETFS HOLDING THIS STOCK

ETFS HOLDING
162
LISTED HERE
26
RANKED BY POSITION SIZE
VTI
0.01% · 6.8M
XBI
1.09% · 6.7M
IWM
0.10% · 4.2M
SCHA
0.07% · 804.0K
DFAS
0.07% · 592.2K
FYC
0.67% · 507.6K
FESM
0.15% · 497.8K
PTH
2.13% · 307.1K
SBIO
2.09% · 268.3K
LABU
0.74% · 243.7K
TMSL
0.12% · 193.2K
CANC
1.64% · 185.1K
XRS2.F
0.10% · 149.7K
RSSL
0.10% · 77.2K
AVSC
0.04% · 58.8K
GSSC
0.09% · 49.7K
BBSC
0.11% · 44.3K
BBC
0.79% · 21.2K
RTWO.L
0.14% · 15.7K
MEDI
0.62% · 14.0K
RFLR
0.25% · 12.5K
ESSC
0.43% · 8.4K
BIB
0.14% · 7.7K
WELP.L
0.94% · 7.4K
BKSE
0.10% · 5.0K
SYZ
0.13% · 4.4K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
78.48%
HOLDERS
336
TOP 12 OF 336 · RANKED BY POSITION SIZE
Sb Investment Advisers (Uk) Ltd
27.9M sh · $236.08M
Fmr LLC
20.1M sh · $376.26M
Commodore Capital LP
17.0M sh · $169.15M
Casdin Capital, LLC
16.0M sh · $300.02M
Blackrock, Inc.
15.3M sh · $286.04M
Point72 Asset Management, L.P.
14.8M sh · $77.12M
Perceptive Advisors LLC
14.1M sh · $263.93M
Blackrock Inc.
10.5M sh · $68.74M
State Street Corp
10.1M sh · $189.47M
Vanguard Group Inc
9.7M sh · $81.99M
Bellevue Group AG
8.3M sh · $43.56M
Tang Capital Management LLC
8.1M sh · $42.12M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book2
Overall Score2

TRADES BY CONGRESS

HOUSE TRADES
Daniel Goldman
Daniel Goldman
Sale
2023-07-12

INSIDER TRADES

★
10 PERCENT OWNER
SVF Pauling (Cayman) Ltd
Sale · 6.0M shares
2026-08-25
★
OFFICER: SEE REMARKS
Rahmer Peter
Sale · 4.5K shares
2026-08-26
★
DIRECTOR, OFFICER: PRESIDENT AND CEO
Patel Sanjiv
Sale · 48.2K shares
2026-08-17
★
OFFICER: CHIEF FINANCIAL OFFICER
Catinazzo Thomas
Sale · 17.7K shares
2026-08-14

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 3
OVERWEIGHT 3
MARKET OUTPERFORM 1
STRONG BUY 1
OUTPERFORM 1
9 GRADES IN THE LAST 12 MONTHS
HC Wainwright & Co. BUY JP Morgan OVERWEIGHT Citizens MARKET OUTPERFORM Barclays OVERWEIGHT Goldman Sachs BUY Guggenheim BUY Raymond James STRONG BUY Oppenheimer OUTPERFORM

SECTORS PEERS

PEERPRICE
AMLX$34.74COMPARE
NKTR$72.52COMPARE
ZBIO$31.27COMPARE
INBX$123.41COMPARE
SNDX$19.54COMPARE
ORIC$13.24COMPARE
IMTX$9.45COMPARE
SANA$3.93COMPARE